DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Evaluate the Efficacy and Safety of Rosuvastatin Versus Simvastatin in Type 2 Diabetic Patients With Dyslipidemia

Information source: Taipei Veterans General Hospital, Taiwan
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Diabetes Mellitus; Dyslipidemia

Intervention: Rosuvastatin (Drug); Simvastatin (Drug)

Phase: Phase 4

Status: Completed

Sponsored by: Taipei Veterans General Hospital, Taiwan

Official(s) and/or principal investigator(s):
Chii-Min Hwu, MD, Principal Investigator, Affiliation: Taipei Veterans General Hospital, Taiwan
Wayne H Sheu, MD,phD, Principal Investigator, Affiliation: Taichung Veterans General Hospital

Summary

This is a phase IV, randomized, open-label, parallel-arm, comparative and forced- titration study to compare the efficacy and safety of rosuvastatin versus simvastatin in patients with type 2 DM and dyslipidemia. When comparing the efficacy of rosuvastatin 20 mg with simvastatin 40 mg for the treatment of type 2 DM with dyslipidemia, rosuvastatin 20 mg is superior to simvastatin 40 mg in achieving the combined goal of LDL-C (<100 mg/dL) and non-HDL-C (<130 mg/dL).

Clinical Details

Official title: A Phase IV, Randomized, Open-label, Parallel-arm, Comparative and Forced- Titration Study to Compare the Efficacy and Safety of Rosuvastatin Versus Simvastatin in Patients With Type 2 DM and Dyslipidemia

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research

Primary outcome: The percentage of patients achieving the combined treatment goal of LDL-C < 100mg/dl and non-HDL-C < 130 mg/dl at week 12 with rosuvastatin treatment compared with simvastatin treatment

Secondary outcome:

Achieving the combined treatment goal of LDL-C (<100 mg/dL) and non-HDL-C (130 mg/dL) at week 4;

Percentage of patients achieving the LDL-C goal of <100 mg/dL at week 4 and week 12;

Percentage of patients achieving the LDL-C goal of <70 mg/dL at Week;The mean percent change from baseline in lipid profile at week 4 and week 12;

Detailed description: The duration of patient participation will be 18 weeks consisting of a 1-week screening period, a 5-week lead-in period, followed by a 12-week treatment period.

Eligibility

Minimum age: 20 Years. Maximum age: 75 Years. Gender(s): Both.

Criteria:

Inclusion Criteria: 1. Male and female between the ages of 20-75 years. 2. Female patients post menopausal, hysterectomized or if of childbearing potential using a reliable method of birth control. 3. Diagnosed with type 2 diabetes mellitus. 4. Fasting triglyceride ≧150 mg/dL ≦500 mg/dL or Non-HDL-C≧130,but≦200 mg/dL 5. Patients receiving stable antidiabetic treatment for 8 weeks before randomization (no change in the category of anti-diabetic agents, but the dose is adjustable). 6. All patients give written informed consent. Exclusion Criteria: 1. A history of hypersensitivity to statins. 2. A history of rhabdomyolysis or hereditary muscle disorders. 3. Insulin-treated patients. 4. Patient with any conditions of acute or chronic pancreatitis. 5. Creatine kinase ≧3-fold upper limit of normal (ULN). 6. Patients with an estimated creatinine clearance (see note)≦30 ml/min or bilirubin ≧1. 5-fold ULN, or chronic active hepatitis or liver function impairment (AST and ALT ≧3-fold ULN). 7. Overt proteinuria (repeat spot urine protein >300mg/dl by dipstick method). 8. Patients are taking cyclosporine. 9. A history of homozygous familial hypercholesterolemia or familial dysbetalipoproteinemia. 10. Patients with alcohol and drug abuse in past 3 years. 11. Serious or unstable medical or psychological conditions. 12. Hypothyroidism (TSH > 5 μIU/mL). 13. In the investigator's opinion, continuation in the study would be detrimental to the patient's well-being or might confound the clinical trial.

Locations and Contacts

Taichung Veterans General Hospital, Taichung, Taiwan

Taipei Veterans General Hospital, Taipei, Taiwan

Additional Information

Starting date: June 2006
Last updated: December 5, 2011

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017